WEBULL
WebtradeDownload

Schrödinger (SDGR) Stock Could Be 30% Undervalued Following Bunsen AI Progress

Simply Wall St · 1d ago

Schrödinger has delivered a sharp 67.7% one year share price gain, which naturally raises a core question for anyone looking at the stock today. Is that move aligned with the cash flows that the business can reasonably generate, based on a Discounted Cash Flow (DCF) view of its intrinsic value?

  • The 67.7% return over the past year puts real pressure on the idea that Schrödinger’s current valuation is still anchored to its cash flow profile.
  • Recent progress with its Bunsen AI co-scientist and broader adoption in pharmaceuticals and materials science may support different expectations for future cash generation and the timing of those inflows.
  • What if you looked at Schrödinger through its sales instead? See why Schrödinger's 8.3x P/S tells a different valuation story.

The issue now is whether the current US$29.82 share price is adequately supported by Schrödinger’s cash flows when viewed through a Discounted Cash Flow (DCF) lens.

To compare Schrödinger’s AI driven drug discovery approach with other listed plays, line it up against 35 healthcare AI stocks.

Does Schrödinger Look Undervalued on Cash Flow?

The Discounted Cash Flow (DCF) approach here takes Schrödinger’s future free cash flows and discounts them back to today in $. The latest twelve month free cash flow shows an outflow of about $118.3 million, and the projections assume the business moves from cash burn to positive free cash generation over time rather than staying in the red indefinitely.

Those forecasts point to free cash flow turning positive by 2030 with further growth in later years. This represents a strong swing from recent history and is a key reason the DCF output sits above the current US$29.82 share price. Because the Q3 2026 update flagged rising software adoption, Bunsen handling most high throughput calculations, and higher guidance for drug discovery revenue, the market may be starting to price in stronger long term cash generation but still not fully closing the gap implied by the cash flow model. Find out what Schrödinger could be worth using our Discounted Cash Flow (DCF) estimate.

The Schrödinger Narrative: What Would Justify Today's Price?

Simply Wall St Narratives for Schrödinger pick up where the DCF puzzle leaves off and explain which assumptions on Schrödinger's growth, profitability and earnings path would need to hold for the stock to be worth meaningfully more or less than today. Each Narrative links a specific fair value to a particular storyline about potential catalysts and key risks, so you can track over time which version of events is actually unfolding on the Community page.

Community views on Schrödinger split between those who see a meaningful margin of safety and those who think expectations already run hot.

Bull case: 7% undervalued

"The shift toward hosted delivery and throughput based licensing, with hosted already close to half of software revenue and a target of 75% within three years..."

Discover why this Narrative puts Schrödinger at 7% undervalued.

Bear case: 15% overvalued

"The significant reduction in software gross margin from 80% to 68% year over year reflects a shift in revenue mix and increased investment in the predictive toxicology initiative..."

Explore why this Narrative puts Schrödinger at 15% overvalued.

Schrödinger’s share price is only one piece of the decision

Before you treat the current valuation as the final word, it is worth asking who is steering Schrödinger, how they are rewarded for key choices, and whether those incentives really align with your interests. See who runs Schrödinger and how they are paid.